Cerity Partners LLC Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Cerity Partners LLC increased its holdings in Hologic, Inc. (NASDAQ:HOLX) by 50.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,884 shares of the medical equipment provider’s stock after buying an additional 20,132 shares during the quarter. Cerity Partners LLC’s holdings in Hologic were worth $4,878,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in shares of Hologic in the second quarter worth $25,000. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter valued at $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic during the 1st quarter worth about $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the 2nd quarter valued at about $37,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.6 %

Shares of HOLX opened at $79.44 on Friday. The stock has a 50 day moving average price of $80.28 and a 200 day moving average price of $78.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The stock has a market capitalization of $18.45 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.51 and a beta of 0.98. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the firm posted $0.89 earnings per share. Equities research analysts forecast that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HOLX shares. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and decreased their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Mizuho cut their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday, October 15th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.